Modern Treatment of Hemophilia: From the Shadows Towards the Light

• References

• 1 Berntrop E, Nilsson IM. Biochemical and in vivo properties of com mercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988; 40: 205-210
• 2 Morfini M, Rafanelli D, Filimberti E, Cinotti S, Piazza E, Longo G, Rossi Ferrini P. Protein content and factor VIII complex in untreated treated and monoclonal factor VIII concentrates. Thromb Res 1989; 56: 169-179
• 3 Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrate. Lancet 1988; 2: 782-785
• 4 Thomas DP. Reducing the risk of virus transmission by blood products. Br J Haematol 1988; 70: 393-395
• 5 Epstein JS, Fricke WA. Current safety of clotting factor concen trates. Arch Pathol Lab Med 1990; 114: 335-340
• 6 White GC, Matthews TJ, Weinhold KJ, Hugues BT, Cromartie HL, McMillan CW, Bolognesi DP. HTLV-III serconversion associated with heat-treated factor VIII concentrate. Lancet 1986; 1: 611-612 (lett).
• 7 van den Berg W, ten Cate JW, Breederveld G, Goudsmit J. Serocon version to HTLV-III in a hemophiliac given heat-treated factor VIII concentrate. Lancet 1986; 1: 803-804
• 8 Mariani G, Ghirardini A, Mandelli F, Verani P, Buttò S, Rossi GB, Mannucci PM. Heated clotting factor and seroconversion for human immunodeficiency virus in three hemophilic patients. Ann Intern Med 1987; 107: 113 (lett).
• 9 Weisser J. Transmission of the human immunodeficiency virus by a dry heat-treated factor VIII concentrate. Klin Pediatr 1988; 200: 375-379
• 10 Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BM, Pegelow CH. The Transfusion Safety Study Group: Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Vox Sang 1990; 59: 129-135
• 11 Remis RJ, O'Shaughnessy MV, Tsoukas C, Growe GH, Schechter MT, Palmer RWH, Lawrence DN. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate. Can Med Assoc J 1990; 142: 1247-1254
• 12 Williams MD, Skidmore SJ, Hill FGH. HIV seroconversion in hemo philic boys receiving heat-treated factor VIII concentrate. Vox Sang 1990; 58: 135-136
• 13 Klein JP, Bailly E, Schneweis KE, Brackmann HH, Hammerstein U, Haufland P, van de Loo B, Oldenburg J. Acute HIV-1 infection in patients with hemophilia B treated with beta-propiolactone UV-inactivated clotting factor. Thromb Haemostas 1990; 64: 336-337 (lett).
• 14 Mannucci PM, Zanetti AR, Colombo M. Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Br J Haematol 1988; 68: 427-30
• 15 Brackmann HH, Egli H. Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate. Lancet 1988; 2: 967 (lett).
• 16 Mannucci PM, Zanetti AR, Colombo M, Chistolini A, De Biasi R, Musso R, Tamponi G. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emonlia. Thromb Haemostas 1990; 64: 232-234
• 17 Schulman S, Lindgren A, Ch Petrini P, Allander T. Transmission of hepatitis C with pasteurized factor VIII. Lancet 1992; 340: 305-306 (lett).
• 18 Schimpf K, Mannucci PM, Kreuz W, Brackmann HH, Auerswald G, Ciavarella N, Moesseler J, De Rosa V, Kraus MD, Brueckman CH, Mancuso G, Mittler V, Haschke F, Morfini M. Absence of hepatitis after treatment with a pasteurized factor VIII. N Engl J Med 1987; 316: 918-922
• 19a Study Group of the UK Hemophilia Center Directors: Effect of dry-heating of coagulation factor concentrates at 80°C for 72 hours on transmission of non-A, non-B hepatitis. Lancet. 1988; 2: 814-816
• 20 Horowitz MS, Rooks C, Horowitz B, Hilgartner M. Virus safety of solvent-detergent treated antihemophilic factor concentrate. Lancet 1988; 2: 186-189
• 21 Mannucci PM, Schimpf K, Brettler DB, Ciavarella N, Colombo M, Haschke F, Lechner K, Lusher JM, Weissbach G. and the Interna tional Study Group: Low risk for hepatitis in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Intern Med 1990; 113: 27-32
• 22 Kreuz W, Auerswald G, Bruckmann C, Zieger B, Linde R, Funk M, Auberger K, Sutor AH, Rasshofer R, Roggendorf FM. Prevention of hepatitis C virus infection in children with hemophilia A and B and von Willebrand's disease. Thromb Haemostas 1992; 67: 189
• 23 Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PBA, Kunschak M, McMillan CW, Preston FE, Rivard GE. and the International Study Group: Low risk of viral infection after administration of vapour heated factor VIII concentrates. Transfusion 1992; 32: 134-138
• 24 Williams MD, Cohen B, Beddal AC, Pasi K, Mortimer PP, Hill FGH. Transmission of parvovirus B19 by coagulation factor concen trates. Vox Sang 1990; 58: 177-181
• 25 Azzi A, Ciappi S, Zakvrezeska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-230
• 26 Mannucci PM. Outbreak of hepatitis A among Italian patients with hemophilia. Lancet 1992: 339-819 (lett).
• 27 Gerritzen A, Scheneweis KE, Brackmann HH, Oldenburg J, Hau-fland P, Gerlich WH, Caspari G. Acute hepatitis A in hemophiliacs. Lancet 1992; 340: 1231-1232 (lett).
• 28 Temperley IJ, Cotter KP, Walsh TJ, Power J, Hillary IB. Clotting factors and hepatitis A. Lancet 1992; 340: 1466 (lett).
• 29 Peerlinck K, Vermylen J. Acute hepatitis A in patients with hemo philia A. Lancet 1993; 341: 179 (lett).
• 30 Rubinstein AI, Rubinstein DB, Coughlin J. Combined solvent/deter gent and 100°C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility. Vox Sang 1991; 60: 60 (lett).
• 31 Carr R, Veitch SE, Edmond E, Peutherer JF, Prescott RJ, Steel CM, Ludlam CA. Abnormalities of circulating lymphocyte subsets in hemophiliacs in an AIDS-free population. Lancet 1989; 334: 1431-1434
• 32 Madhok R, Grade A, Lowe GDO, Burnett A, Froebel K, Follett E, Forbes CD. Impaired cell mediated immunity in the absence of infection with human immunodeficiency virus. Br Med J 1986; 293: 978-980
• 33 Teitel JM, Freedman JJ, Garvey MB, Kardish M. Two-year evalua tion of clinical and laboratory variables of immune function in 117 hemophiliacs seropositive or seronegative for HIV-1. Am J Hematol 1989; 32: 262-272
• 34 Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative hemophiliacs: relation ship to blood product therapy. Br J Haematol 1992; 80: 364-369
• 35 Sullivan JL, Brewster FE, Brettler DB, Forsberg AD, Cheeseman SH, Byron KS, Balcer SM, Willits DL, Lew RA, Levine PH. Hemo philiac immunodeficiency: influence of exposure to factor VIII con centrate, LAV/HTLV-III and herpes virus. J Pediatr 1986; 108: 504-510
• 36 Horsburg CR, Davis KC, Hasiba U, Weiss SH, Goedert JJ, Jarin P, Kirkpatrick CH. Altered immunity in hemophilia is correlated with the presence of antibody to human T-cell lymphotropic virus type III (HTLV-III). J Clin Immunol 1986; 6: 37
• 37 Eyster ME, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ. Nat ural history of human immunodeficiency virus infections in hemo philiacs: effects of T-cell subsets, platelet counts and age. Ann Intern Med 1987; 107: 1-6
• 38 Brettler DB, Forsberg AD, Brewster FE, Sullivan JL, Levine PH. Delayed cutaneous hypersensitivity reaction in hemophilic subjects treated with factor concentrate. Am J Med 1986; 81: 607-611
• 39 Margolick JB, Volkman DJ, Folks TM. HTLV-III/LAV detection by antigen induced activation of T-cells and amplification of direct sup pression by virus of lymphocyte blastogenic responses. J Immunol 1987; 138: 1719-1728
• 40 Lederman MM, Saunders C, Toossi Z, Lemon N, Everson B. Rat-noff OD: Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 1986; 107: 471-478
• 41 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in hemophiliacs. Br J Haematol 1989; 71: 387-91
• 42 Eibl MM, Ahamad R, Wolf VM, Linnau Y, Gotz E, Mannhalter JW. A component of factor VIII preparations which can be separated fram factor VIII activity down modulates human monocyte function. Blood 1987; 69: 1153-60
• 43 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIIIC concentrate purified from plasma using monoclon al antibodies: human studies. Blood 1989; 73: 1859-1863
• 44 De Biasi R, Rocino A, Miraglia E, Mastrullo R, Quirino A. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1992; 78: 1919-1922
• 45 Seremetis S, Aledort LM, Bona R, Bray G, Brettler DB, Eyster E, Kessler C, Lusher J, Rickles F, Sacks H. A three-year randomized prospective study of high or intermediate purity factor VIII concen trates in asymptomatic HIV+ hemophiliacs: effects on immune func tion. Blood 1992; 80 (Suppl. 01) 366a
• 46 Mannucci PM, Gringeri A, De Biasi R, Baudo F, Morfini M, Ciavarella N. Immune status of asymptomatic HIV-infected hemo philiacs: randomized, prospective two-year comparison of treatment with a high-purity or an intermediate purity factor VIII concentrate. Thromb Haemostas 1992; 67: 310-313
• 47 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker CB, Orr EC, Amphlett GW, Foster B, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molec ular cloning of a cDNA encoding human antihemophilic factor. Nature 1984; 312: 342-347
• 48 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion K, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337
• 49 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing and secretion of recombinant human factor VIII expressed in mam malian cells. J Biol Chem 1988; 263: 6351-6362
• 50 Klein U. Production and characterization of recombinant factor VIII. Sem Hematol 1991; 28 (Suppl. 01) 17-21
• 51 Fournel M. Preclinical and in vivo studies of rFVIII. Sem Hematol 1990; 28 (Suppl. 01) 22-26
• 52 Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood 1988; 72: 335-342
• 53 White II GC, Mc Millan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-170
• 54 Schwartz RS, Abildgaard C, Aledort LM, Arkin S, Bloom A, Brackmann H, Brettler D, Dietrich S, Egli J, Hilgartner M, Inwood M, Kasper C, Kernoff P, Levine P, Lusher JM, Mannucci PM, Rose E, Scharrer I. Human recombinant DNA derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-1805
• 55 Goldsmith JC and the Recombinate Study Group: Clinical trial of Recombinate: safety and efficacy of a genetically engineered anti hemophilic factor in previously treated patients. Blood. 1991; 78 (Suppl. 01) 64a
• 56 Lusher JM, Arkin S, Abildgaard CF. Schwartz RS and the Kogenate Previously Untreated Patients Study Group: Recombinant factor VIII for the treatment of previously untreated patients with hemo philia A. Safety, efficacy and development of inhibitors. N Engl J Med 1993; 328: 453-459
• 57 Bray GL, Liu-Maruya S, Courter S, High K, Gomperts E. and the Recombinate Study Group: Experience with recombinant factor VIII (Recombinate) in previously untreated patients (PUPs) with severe hemophilia A. Blood 1992; 80 (Suppl. 01) 229a
• 58 Lusher JM, Salzman PM. and the Monoclate Study Group: Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Sem Hematol 1990; 27 (Suppl. 02) l-8
• 59 Addiego SE, Gomperts E, Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIC immunoaffinity chromatography. Thromb Haemostas 1992; 67: 19-27
• 60 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Brackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitor in hemophiliacs. Lancet 1992; 339: 594-598
• 61 Kasper CK. Thromboembolic complications. Thromb Diath Haem-orrh 1975; 33: 640-648
• 62 Magner A, Aronson DL. Toxicity of factor IX concentrates in mice. Devel Biol Stand 1979; 44: 185-189
• 63 Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Tri-antaphyllopoulos DC, Kosow DP. Coagulation factor IX concen trate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-1227
• 64 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of high ly purified human plasma factor IX:C therapeutic concentrate pre pared by conventional chromatography. Vox Sang 1989; 57: 225-232
• 65 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin is not increased in the blood of hemophilia B patiens after the infusion of a purified factor IX con centrate. Blood 1991; 76: 2540-2545
• 66 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concen trate. Br J Haematol 1991; 79: 606-611
• 67 Bardin JM, Sultan Y. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion 1990; 30: 441-443
• 68 Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor IX: suc cessful surgical experience with a purified factor IX concentrate. Am J Hematol 1992; 40: 210-217
• 69 Kim HC, McMillan CW, White GC, Bergman GE, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison with prothrombin complex concen trates. Blood 1992; 79: 568-572